Processing

Please wait...

Settings

Settings

Goto Application

1. WO2012065161 - ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 8

Publication Number WO/2012/065161
Publication Date 18.05.2012
International Application No. PCT/US2011/060583
International Filing Date 14.11.2011
IPC
A61K 39/395 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
CPC
A61K 39/39558
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies
39533against materials from animals
39558against tumor tissues, cells, antigens
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/6809
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
6807the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
6809Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
A61K 47/6811
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
6811the drug being a protein or peptide, e.g. transferrin or bleomycin
A61K 47/6849
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6849the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
A61K 47/6851
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
68the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
6835the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
6851the antibody targeting a determinant of a tumour cell
Applicants
  • SCOTT & WHITE HEALTHCARE [US]/[US] (AllExceptUS)
  • THE GOVERNMENT OF THE UNITED STATES OF AMERICA [US]/[US]
  • WAKE FOREST UNIVERSITY SCHOOL OF MEDICINE [US]/[US]
  • FRANKEL, Arthur, E. [US]/[US] (UsOnly)
  • SU, Yunpeng (UsOnly)
  • ST. CROIX, Brad (UsOnly)
  • LEPPLA, Stephen H. [US]/[US] (UsOnly)
Inventors
  • FRANKEL, Arthur, E.
  • SU, Yunpeng
  • ST. CROIX, Brad
  • LEPPLA, Stephen H.
Agents
  • SHISHIMA, Gina, N.
Priority Data
61/412,99912.11.2010US
61/527,33925.08.2011US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ANTIBODIES TO TUMOR ENDOTHELIAL MARKER 8
(FR) ANTICORPS CONTRE LE MARQUEUR 8 ENDOTHÉLIAL TUMORAL
Abstract
(EN)
The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.
(FR)
La présente invention concerne des anticorps particuliers et leurs fragments qui trouvent une utilisation dans la détection, la prévention et le traitement de maladies et de troubles associés à une angiogenèse anormale. En particulier, ces anticorps détectent le marqueur 8 endothélial tumoral (TEM8) sous sa forme native et sa forme exprimée à la surface cellulaire. L'invention concerne également des procédés améliorés de production d'anticorps monoclonaux, ainsi que des compositions pharmaceutiques et des nécessaires.
Also published as
Latest bibliographic data on file with the International Bureau